Skip to main content
. 2017 Mar 15;37(5):2663–2671. doi: 10.3892/or.2017.5509

Figure 4.

Figure 4.

Pyrophosphate sequencing pattern of the Wnt5a promoter in AML patients and normal controls. (A) The CpG islands of the Wnt5a promoter in the AML patients are highly methylated. (B) The CpG islands of the Wnt5a promoter in the AML patients are lowly methylated. AML, acute myeloid leukemia.